Program
Overview
Program Overview
In its twenty-first year, IHV2019 will convene to address strategies to end the HIV/AIDS epidemic, and the intersection of HIV and opioid use disorder (OUD). The conference will open by highlighting the recent plan for "Ending the HIV Epidemic" by 2030, with expert opinions from Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases (NIAID), Nora Volkow, MD, Director, National Institute of Drug Abuse (NIDA) and Dr. Carl Diffenbach, Director of Division of AIDS, NIAID.
A critical component of ending the HIV epidemic is successful implementation of prevention strategies. Sexual education, condoms, syringe exchange, and pre-exposure prophylaxis will be reviewed, along with challenges and possibilities in wide-spread implementation. In addition, various agencies will describe the utilization of broad epidemiologic approaches to solidify our understanding of HIV in America.
With the rising opioid epidemic in the United States, resulting in localized HIV outbreaks, the impact of OUD on HIV is increasingly relevant. Dr. Nora Volkow, Director of the National Institute of Drug Abuse, will give a special lecture on the subject. Speakers will discuss strategies specific to addressing HIV in patients who inject drugs (PWID), incorporating treatment of OUD into infectious disease practice, and the value of harm reduction strategies, such as supervised injection facilities, in improving outcomes in PWID.
Thursday, October 3
Day 1: Thursday, October 3, 2019
Topic: Zero Transmission
Session A – Responses to the HIV/AIDS Epidemic
In February 2019, multiple agencies within the federal government together announced a new initiative to address the HIV epidemic, setting the goal of a 90 percent reduction in incident HIV by 2029. The “Ending the HIV Epidemic” pathway is based in four pillars: (1) Diagnose, with an emphasis on early detection; (2) Treat, initiating ART rapidly; (3) Protect, utilizing prevention strategies such as PrEP; and (4) Respond, detecting new HIV clusters. The initial phase of the initiative will target 48 counties that serve as hotspots of new infection across the US. In this session, Dr. Carl Dieffenbach, Director of Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID); Dr. Anthony Fauci, Director of NIAID; and Dr. Robert Redfield, Director of the Centers for Disease Control (CDC) and Institute of Human Virology (IHV) Founding Member, will detail this ambitious response.
Chairpersons and Discussants:
Shyam Kottilil, MBBS, PhD, Institute of Human Virology, University of Maryland School of Medicine, US
Salim Abdool Karim, MBChB, PhD, DSc, CAPRISA, ZA
Schedule:
9:00 AM
Welcome, Session Comments
Robert Gallo, MD, Institute of Human Virology, University of Maryland School of Medicine, US
9:10 AM
Special Lecture: Ending the HIV Epidemic: A Plan for America
Speaker: ADM Brett Giroir, MD, US Department of Health & Human Services
9:45 AM
Panel Discussion, Questioning and Answering
9:55 AM
Special Lecture: HIV in 2019: Optimizing the HIV Treatment and Prevention Toolkits
Speaker: Anthony Fauci, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US
10:30 AM
Panel Discussion, Questioning and Answering
Coffee Break, 10:40 AM - 11:00 AM
11:00 AM
Special Lecture: Epidemic Control and Beyond: What Will it Take to Truly End the HIV Epidemic
Speaker: Carl Dieffenbach, PhD, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US
11:35 AM
Panel Discussion, Questioning and Answering
11:45 AM
Closing Remarks
Speaker: Salim Abdool Karim, MBChB, PhD, DSc, CAPRISA, ZA
Lunch Break, 11:50 AM – 1:00 PM
Session B – HIV/AIDS Prevention Strategies
Despite progress in reducing incident HIV in the United States, there remains a disproportionate rise amongst marginalized populations including black and Latino MSM, persons who inject drugs (PWID), black female heterosexuals, and transgender individuals, and a concentration of these new cases in the South. As such, there is a renewed interest in evidence-based prevention strategies to target these populations, many of whom remain out of medical care. In this session, prevention strategies including sexual education, condoms, syringe exchange, and pre-exposure prophylaxis will be reviewed, along with challenges and possibilities in wide-spread implementation.
Chairpersons and Discussants:
Mario Stevenson, PhD, University of Miami, US
Ken Mayer, MD, The Fenway Institute, US
Schedule:
1:00 PM
Presentation Title: Syringe Service Programs: Venues for Comprehensive Harm Reduction
Speaker: John Brooks, MD, Centers for Disease Control and Prevention, US
1:20 PM
Presentation Title: The Next Generation of HIV Prevention Strategies: Getting Closer to Zero
Speaker: Myron Cohen, MD, University of North Carolina at Chapel Hill, US
1:40 PM
Presentation Title: HIV Prevention 2019: What will it take to get to zero?
Speaker: Ken Mayer, MD, The Fenway Institute, US
2:00 PM
Presentation Title: New Approaches to Antiretroviral
Speaker: Michael Saag, MD, University of Alabama at Birmingham, US
2:20 PM
Panel Discussion, Questioning and Answering
Coffee Break, 2:40 PM - 3:00 PM
Session C – HIV/AIDS Epidemiology
HIV Epidemiology is utilized to not only understand the current state of infection, but to target interventionand prevention efforts. Through molecular sequencing, the field has undergone a transition, enabling transmission mapping and analysis of risk on a scale broader than ever before. At the same time, the epidemiology of HIV/AIDS remains highly connected to individual behavioral patterns, underscoring the role of public health departments in testing and education. In this session, various agencies will describe the utilization of broad epidemiologic approaches to solidify our understanding of HIV in America.
Chairpersons and Discussants:
William Blattner, MD, Salt Run Global, US
Anders Vahlne, MD, PhD, Karolinska Institute, SE
Schedule:
3:00 PM
Presentation Title: Population-based HIV Impact Assessments: Using the survey data to precisely target response
Speaker: Manhattan Charurat, PhD, Institute of Human Virology, University of Maryland School of Medicine, US
3:20 PM
Presentation Title: Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles is Impaired by Mannose Binding Lectin
Speaker: John Moore, PhD, Weill Medical College of Cornell University, US
3:40 PM
Presentation Title: How would you like your PrEP? The fit of new HIV prevention tools to lived sexual lives.
Speaker: Chris Beyrer, MD, Johns Hopkins Bloomberg School of Public Health, US
4:00 PM
Presentation Title: HIV cluster and outbreak response: Using molecular and other HIV data to refine prevention efforts and improve health
Speaker: Alexandra Oster, MD, Centers for Disease Control and Prevention, US
4:20 PM
Presentation Title: Progress towards ending the HIV epidemic in Baltimore: Insights from 15 years of HIV behavioral surveillance
Speaker: Danielle German, PhD, Johns Hopkins Bloomberg School of Public Health, US
4:40 PM
Panel Discussion, Questioning and Answering
Opening Reception and Poster Session, 5:15 PM - 7:30 PM
Friday, October 4
Day 2: Friday, October 4, 2019
Topic: Opioid Intersection
Session D – Epidemiology of HIV-Opioid Intersection
There is a rising opioid epidemic in the United States, marked by staggering rates of opioid overdose death. While rates of HIV acquisition attributable to drug use have declined over the past decade, this rise of opioid misuse, and in particular, injecting drug use, has resulted in localized HIV outbreaks. This session will focus on the epidemiology of the overlapping epidemics of HIV and opioid use disorder (OUD). Dr. Nora Volkow, Director of the National Institute of Drug Abuse, will open this session with a special lecture on the subject.
Chairpersons and Discussants:
Robert Gallo, MD, Institute of Human Virology, University of Maryland School of Medicine, US
Leonid Margolis, PhD, National Institute of Child Health and Human Development, National Institutes of Health, US
Schedule:
9:00 AM
Introduction
The Honorable Bill Ferguson, Maryland State Senate, District 46, Baltimore City
The Honorable Brooke Lierman, Maryland House of Delegates, District 46, Baltimore City
9:10 AM
Special Lecture: Impact of the Opioid Crisis in HIV Transmission and Outcomes
Speaker: Nora Volkow, MD, National Institute of Drug Abuse, National Institutes of Health, US
9:40 AM
Presentation Title: New Compound with Novel CNS Mechanism Blocks Craving and Drug-Seeking in Addiction
Speaker: Ivan Diamond, MD, PhD, Amygdala Neurosciences, Inc., US
10:00 AM
Presentation Title: An Open-label, Randomized, Single-dose, 2-period, 2-treatment Crossover Bioavailability Study Comparing 5 mg/0.5 mL of Intramuscular Naloxone Hydrochloride to 2 mg/0.4 mL Intramuscular Naloxone Hydrochloride Auto-injector in Healthy Subjects
Speaker: Ronald Moss, MD, PhD, Adamis Pharmaceuticals Corporation, US
10:20 AM
Panel Discussion, Questioning and Answering
Coffee Break, 10:40 AM - 11:00 AM
Session E – Closing the Gap
The ongoing transmission of viral infections in people who inject drugs is, in large part, a result of gaps in access to treatment and evidence based harm reduction strategies. In order to meaningfully interrupt HIV transmission in PWID, strides need to be made to close gaps in care for this marginalized population, including addressing OUD as part of infectious disease care. Speakers will discuss strategies specific to addressing HIV in PWID, incorporating treatment of OUD into infectious disease practice, and the value of harm reduction strategies, such as supervised injection facilities, in improving outcomes in PWID.
Chairpersons and Discussants:
Glen Treisman, MD, PhD, Johns Hopkins Medicine, US
Carlos Del Rio, MD, Emory University, US
Schedule:
10:50 AM
Presentation Title: Injection drug use and HIV in Baltimore City: Trends and future projections
Speaker: Shruti Mehta, PhD, Johns Hopkins Bloomberg School of Medicine, US
11:10 AM
Presentation Title: Treating Opioid Use Disorder in the Criminal Justice System
Speaker: Josiah Rich, MD, MPH, Brown University, US
11:30 AM
Presentation Title: Keeping PWUD Safe and Alive
Speaker: Mark Eisenberg, MD, MGH Charlestown Healthcare Center, US
11:50 AM
Panel Discussion, Questioning and Answering
Lunch Break, 12:05 PM - 1:30 PM
Chairperson and Discussant:
Linda Chang, MD, University of Maryland School of Medicine, US
Manhattan Charurat, PhD, Institute of Human Virology, University of Maryland School of Medicine, US
1:30 PM
Presentation Title: Collocation of HCV and OUD Treatment: The ANCHOR Study
Speaker: Elana Rosenthal, MD, Institute of Human Virology, University of Maryland School of Medicine, US
1:50 PM
Presentation Title: Integrating care for Opioid Use Disorders to Tackle Infectious Disease Epidemics
Speaker: Carlos Del Rio, MD, Emory University, US
2:10 PM
Presentation Title: The opiate epidemic-how we got here and how do we get out
Speaker: Glen Treisman, MD, PhD, Johns Hopkins Medicine, US
2:30 PM
Presentation Title: IDU, HIV and Viral Hepatitis in Florida: Challenges and Opportunities
Speaker: Emmanuel Thomas, MD, PhD, University of Miami, US
2:50 PM
Panel Discussion, Questioning and Answering
Coffee Break, 3:10 PM – 3:30 PM
Session F – Lifetime Achievement Award Mini-Symposium
The 2019 IHV Lifetime Achievement Award for Scientific Contributions is given to Warner Greene, MD, PhD, Director, Gladstone Center for HIV Cure Research, most known for his groundbreaking research studies on human retroviruses beginning with HTLV-1 and then on to HIV, as well as the founding and emeritus director of the Gladstone Institute of Virology and Immunology.
The 2019 IHV Lifetime Achievement Award for Public Service is given to The Honorable Parris Glendening, former Maryland Governor and The Honorable Kathleen Kennedy Townsend, former Maryland Lieutenant Governor, who were instrumental in establishing the Institute of Human Virology in 1996. Mrs. Kennedy Townsend was Chair of the IHV Board of Advisors and is currently a member. Since IHV’s inception, both have remained strong advocates of its research and clinical efforts.
Chairpersons and Discussants:
Robert Mahley, MD, PhD, Gladstone Institutes, US
Henry Masur, MD, National Institute of Health Clinical Center, US
Schedule:
3:30 PM
Introduction to Lifetime Achievement Awards
Robert Gallo, MD, Institute of Human Virology, University of Maryland School of Medicine, US
3:40 PM
Honorary Lecture on Behalf of Warner Greene: The γc family of cytokines and fine-tuning their signals
Speaker: Warren Leonard, MD, National Heart, Lung and Blood Institute, National Institutes of Health, US
4:10 PM
Honorary Lecture on Behalf of Warner Greene: Impact of combination HIV interventions on HIV incidence in Uganda: a prospective cohort study
Speaker: Thomas Quinn, MD, Johns Hopkins Center for Global Health, US
4:40 PM
Reinhard Kurth Lecture: Attacking the the Latent HIV Reservoir with Convertible CAR-T Cells Programmed with Broadly Neutralizing Antibodies
Speaker: Warner Greene, MD, PhD, Gladstone Center for HIV Cure Research, US
Break before Gala Reception, 5:10 PM - 6:00 PM
Gala Reception, 6:00 PM/Lifetime Achievement Award Dinner, 6:45 PM